



IBA Dosimetry's Compass Patient QA Endures Successful Outreach to the UK & Ireland Medical Physicist Community

User Meeting enables physicists in the UK to perform effective treatment verification & patient dose analysis

Schwarzenbruck, May 13, 2015 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, has showcased delegates of the UK & Ireland Medical Physics Community the 3D patient specific QA utilizing Compass. The co-hosted meeting by Queen's Hospital in Romford and OSL (Oncology Systems Limited) included a presentation on myQA global quality assurance platform, Compass and the new Stealth Chamber reference detector.

*"To improve our patient QA workflow, we were investigated for a better verification solution for complex rotational and fixed beam IMRT plans. We performed a literature survey for the best Patient QA for our needs i.e. a solution that integrates both, software based patient QA that allows us to do an independent secondary TPS check as well as a solution that allows us to measure the treatment dose to ensure the whole treatment chain from TPS to Linac delivery is verified" said **PhD Ghirmay Kidane, Consultant Radiotherapy Physicist at BHR Hospitals, United Kingdom.** "The Compass system has satisfied our clinical requirement. It is such an exciting tool to use which provides us crucial calculation time saving and therefore much faster QA workflow. The dose calculation of a 2 full arc VMAT is done in approximately 3 to 4 minutes. The powerful collapsed cone algorithm provided a TPS-class dose calculation on real patient CT as well as CT based DVH and 3-D Gamma. It also has a 2D workspace for quick fluence comparisons with familiar feature with 2D planar profile analysis tools which features the dose distribution in relative or absolute dose modes. It also provides a map of gamma distributions between the TPS plan and compass re-calculated plan".*

*"We were very excited to co-host the UK IBA users' meeting with OSL Ltd, and this was the ideal opportunity to share our early experiences with the use of COMPASS with colleagues from across the UK", said **MSc Liz Crees, Deputy Head of Radiotherapy Physics of Queen's Hospital in Romford, United Kingdom.** "We were fortunate to have presentations from other Compass users and from centres who had been commissioning the new Stealth chamber and the Dolphin system. IBA speakers gave very knowledgeable presentations on the different IBA product ranges and were the available throughout the day to discuss individual questions. This was a very useful and enjoyable meeting combining presentations, practical sessions and the ability to network and share experience with other IBA users from throughout the UK".*

*"The meeting has given me of a more clinical angle on how the devices work", said **Rog Cannon, Technical Support Engineer at OSL.** "It has been a very good meeting and I enjoyed participating. It has given me a more in-depth idea as to what goes on behind the scenes and how they are actually used in a clinical environment. That for me personally is quite fascinating because it has given me the opportunity to see how my engineering tasks come into practice and benefit the greater goal of patient care".*

*"Being part of the UK & Ireland User Meeting has enabled IBA to display how patient quality assurance can be done simpler and with more confidence", said **Ralf Schira, Vice President Marketing at IBA Dosimetry.** "We care to deliver leading edge technology solutions for radiotherapy applications and it is good to see how well received it was".*

To find out more about Dolphin visit <http://www.iba-dosimetry.com/complete-solutions/online-treatment-monitoring>



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Media Contact:

Priscilla Alvarez Ulate
Marketing Communication Specialist
IBA Dosimetry
Priscilla.Alvarez-Ulate@iba-dosimetry.com

<http://www.iba-dosimetry.com>

Press release | **May 13, 2015**

###